Prominent cardioprotective effects of third generation beta blocker nebivolol against anthracycline-induced cardiotoxicity using the model of isolated perfused rat heart

European Journal of Cancer

Volumn 44, Issue 3, 2008, Pages 334-340

  de Nigris, Filomena ^a   Rienzo, Monica ^a   Schiano, Concetta ^a   Fiorito, Carmela ^b   Casamassimi, Amelia ^a   Napoli, Claudio ^a  

^a Excellence Research Center on Cardiovascular Diseases   (Italy)

^b IRCCS MULTIMEDICA   (Italy)

Author keywords

Anthracyclines; Beta blockers; Heart

Indexed keywords

CARVEDILOL; CREATINE KINASE; DAUNORUBICIN; DOXORUBICIN; GLUTATHIONE; GLUTATHIONE DISULFIDE; GLUTATHIONE PEROXIDASE; GLUTATHIONE REDUCTASE; MANGANESE SUPEROXIDE DISMUTASE; NEBIVOLOL; NITRATE; NITRITE; TROPONIN T;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARDIOTOXICITY; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVITY; HEART LEFT VENTRICLE PRESSURE; HEART PERFUSION; HEART PROTECTION; MALE; MONOTHERAPY; NONHUMAN; OXIDATIVE STRESS; PERFUSION PRESSURE; PRIORITY JOURNAL; RAT;

ADRENERGIC BETA-ANTAGONISTS; ANALYSIS OF VARIANCE; ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; BENZOPYRANS; CARBAZOLES; DAUNORUBICIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMBINATIONS; DRUG EVALUATION, PRECLINICAL; ETHANOLAMINES; GLUTATHIONE; HEART DISEASES; MALE; NITRATES; OXIDATIVE STRESS; PROPANOLAMINES; RATS; RATS, SPRAGUE-DAWLEY;

EID: 38949200975     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2007.12.010     Document Type: Article

References (23)

1. Minotti G., Menna P., Salvatorelli E., Cairo G., and Gianni L. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev 56 (2004) 185-229
2. Hasinoff B.B., Hellmann K., Herman E.H., and Ferrans V.J. Chemical, biological and clinical aspects of dexrazoxane and other bisdioxopiperazines. Curr Med Chem 5 (1998) 1-28
3. Matsui H., Morishima I., Numaguchi Y., Toki Y., Okumura K., and Hayakawa T. Protective effects of carvedilol against doxorubicin-induced cardiomyopathy in rats. Life Sci 65 (1999) 1265-1274
4. Kalay N., Basar E., Ozdogru I., et al. Protective effects of carvedilol against anthracycline-induced cardiomyopathy. J Am Coll Cardiol 48 (2006) 2258-2262
5. Napoli C., De Nigris F., Cicala C., et al. Protease-activated receptor-2 activation improves efficiency of experimental ischemic preconditioning. Am J Physiol 282 (2002) H2004-H2010
6. Napoli C., Cicala C., Wallace J.L., et al. Protease-activated receptor-2 modulates myocardial ischemia-reperfusion injury in the rat heart. Proc Natl Acad Sci U S A 97 (2000) 3678-3683
7. Poun P., Bonoron-Adele S., Gouverneur G., Tariosse L., Besse P., and Robert J. Development of the model of rat isolated perfused heart for the evaluation of anthracyline cardiotoxicity and its circumvention. Br J Pharmacol 117 (1996) 1593-1599
8. Platel D., Pouna P., Bonoron-Adele S., and Robert J. Comparative cardiotoxicity of idarubicin and doxorubicin using the isolated perfused rat heart model. Anticancer Drugs 10 (1999) 671-676
9. Robert J. Preclinical assessment of anthracycline cardiotoxicity in laboratory animals: Predictiveness and pitfalls. Cell Biol Toxicol 23 (2007) 27-37
10. Ignarro L.J., Cirino G., Casini A., and Napoli C. Nitric oxide as a signaling molecule in the vascular system: an overview. J Cardiovasc Pharmacol 34 (1999) 879-886
11. Mason R.P., Kalinowski L., Jacob R.F., Jacoby A.M., and Malinski T. Nebivolol reduces nitroxidative stress and restores nitric oxide bioavailability in endothelium of black Americans. Circulation 112 (2005) 3795-3801
12. Gielen W., Cleophas T.J., and Agrawal R. Nebivolol: a review of its clinical and pharmacological characteristics. Int J Clin Pharmacol Ther 44 (2006) 344-357
13. Ghio S., Magrini G., Serio A., et al. SENIORS investigators. Effects of nebivolol in elderly heart failure patients with or without systolic left ventricular dysfunction: results of the SENIORS echocardiographic substudy. Eur Heart J 27 (2006) 562-568
14. Napoli C., Williams-Ignarro S., De Nigris F., et al. Long-term combined beneficial effects of physical training and metabolic treatment on atherosclerosis in hypercholesterolemic mice. Proc Natl Acad Sci U S A 101 (2004) 8797-8802
15. Shan K., Lincoff A.M., and Young J.B. Anthracycline-induced cardiotoxicity. Ann Intern Med 125 (1996) 47-58
16. Herman E.H., Zhang J., Lipshultz S.E., et al. Correlation between serum levels of cardiac troponin-T and the severity of the chronic cardiomyopathy induced by doxorubicin. J Clin Oncol 17 (1999) 2237-2243
17. Carreira R.S., Monteiro P., Gon Alves L.M., and Providencia L.A. Carvedilol: just another Beta-blocker or a powerful cardioprotector?. Cardiovasc Hematol Disord Drug Targets 6 (2006) 257-266
18. Mukai Y., Yoshida T., Nakaike R., et al. Five cases of anthracycline-induced cardiomyopathy effectively treated with carvedilol. Intern Med 43 (2004) 1087-1088
19. Weber M.A. The role of the new beta-blockers in treating cardiovascular disease. Am J Hypertens 18 (2005) 169S-176S
20. Goldhammer E., Maor I., Shnitzer S., Lanir A., and Abinader E.G. The early anti-oxidant effect of carvedilol predicts the clinical course in congestive heart failure patients. J Cardiovasc Med 8 (2007) 453-456
21. Pedersen M.E., and Cockcroft J.R. The vasodilatory beta-blockers. Curr Hypertens Rep 9 (2007) 269-277
22. de Boer R.A., Voors A.A., and van Veldhuisen D.J. Nebivolol: third-generation beta-blockade. Expert Opin Pharmacother 8 (2007) 1539-1550
23. McMahon C.J., Murchan H., Prendiville T., and Burch M. Parvovirus B19 infection associated with dilated cardiomyopathy in patients with previous anthracycline exposure. Pediatr Cardiol 28 (2007) 394-395